Journal article Open Access

Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool

Vicente Herrero-Aguayo; Prudencio Sáez-Martínez; Juan M Jiménez-Vacas,; M Trinidad Moreno-Montilla; Antonio J Montero-Hidalgo; Jesús M Pérez-Gómez; Juan L López-Canovas; Francisco Porcel-Pastrana; Julia Carrasco-Valiente; Francisco J Anglada; Enrique Gómez-Gómez; Elena M Yubero-Serrano; Alejandro Ibañez-Costa; Aura D Herrera-Martínez; André Sarmento-Cabral; Manuel D Gahete; Raúl M Luque

Prostate-specific antigen (PSA) is the gold-standard marker to screen prostate cancer (PCa) nowadays. Unfortunately, its lack of specificity and sensitivity makes the identification of novel tools to diagnose PCa an urgent medical need. In this context, microRNAs (miRNAs) have emerged as potential sources of non-invasive diagnostic biomarkers in several pathologies. Therefore, this study was aimed at assessing for the first time the dysregulation of the whole plasma miRNome in PCa patients and its putative implication in PCa from a personalized perspective (i.e., obesity condition). Plasma miRNome from a discovery cohort (18 controls and 19 PCa patients) was determined using an Affymetrix-miRNA array, showing that the expression of 104 miRNAs was significantly altered, wherein six exhibited a significant receiver operating characteristic (ROC) curve to distinguish between control and PCa patients (area under the curve [AUC] = 1). Then, a systematic validation using an independent cohort (135 controls and 160 PCa patients) demonstrated that miR-107 was the most profoundly altered miRNA in PCa (AUC = 0.75). Moreover, miR-107 levels significantly outperformed the ability of PSA to distinguish between control and PCa patients and correlated with relevant clinical parameters (i.e., PSA). These differences were more pronounced when considering only obese patients (BMI > 30). Interestingly, miR-107 levels were reduced in PCa tissues versus non-tumor tissues (n = 84) and in PCa cell lines versus non-tumor cells. In vitro miR-107 overexpression altered key aggressiveness features in PCa cells (i.e., proliferation, migration, and tumorospheres formation) and modulated the expression of important genes involved in PCa pathophysiology (i.e., lipid metabolism [i.e., FASN] and splicing process). Altogether, miR-107 might represent a novel and useful personalized diagnostic and prognostic biomarker and a potential therapeutic tool in PCa, especially in obese patients.

Files (3.8 MB)
Name Size
mmc2.pdf
md5:9e1cb1c49cf7828adb19d3adf6816e5c
3.8 MB Download
39
29
views
downloads
Views 39
Downloads 29
Data volume 111.5 MB
Unique views 33
Unique downloads 25

Share

Cite as